Aquestive Therapeutics Inc. (AQST) Misses Q3 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aquestive Therapeutics (AQST) PT Raised to $24 at RBC Capital
November 7, 2018 7:09 AM ESTRBC Capital analyst Randall Stanicky raised the price target on Aquestive Therapeutics (NASDAQ: AQST) to $24.00 (from $23.00) while maintaining an Outperform rating following results.
Stanicky said pending Sympazan launch set to pave the way for lead product Libervant next year.
... More